The FDA approved pembrolizumab for certain women with microsatellite instability-high or mismatch repair-deficient advanced endometrial cancer.
The latest approval of pembrolizumab (Keytruda, Merck), an anti-PD-1 therapy, applies to women who experience disease progression after previous systemic therapy in any setting and do not qualify for curative surgery or radiation, according to a press release from the manufacturer.
New data from Cohorts D and K of the KEYNOTE-158 trial served as the basis for approval. The cohorts enrolled 90 women with unresectable or metastatic microsatellite